MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)

Neuropharmacology

Volumn 92, Issue , 2015, Pages 158-169

  Parsons, Christopher G ^a   Ruitenberg, Maarten ^a   Freitag, Christine E ^a   Sroka Saidi, Kamila ^a   Russ, Hermann ^a   Rammes, Gerhard ^b  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Age related macular degeneration (AMD); Aggregation modulator; Alzheimer's disease; Atomic force microscopy (AFM); Dynamic light scattering (DLS); Fluorescence resonance energy transfer (TR FRET); Glaucoma; Oligomers; SDS PAGE; amyloid

Indexed keywords

DIPEPTIDE; MONOMER; MRZ 99030; OLIGOMER; UNCLASSIFIED DRUG; 2-(2-AMINO-3-(1H-INDOL-3-YL)PROPIONYLAMINO)-2-METHYLPROPIONIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MELANIN; PEPTIDE FRAGMENT; TRITIUM;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; ARTICLE; ATOMIC FORCE MICROSCOPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; EPITHELIUM CELL; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLAUCOMA; LIGHT SCATTERING; NEUROPROTECTION; NONHUMAN; PC12 CELL LINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RETINA GANGLION CELL; TIME RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MOUSE; NEUROBLASTOMA; PATHOLOGY; SILVER STAINING; SPECTROSCOPY; SURFACE PLASMON RESONANCE; TIME; TUMOR CELL LINE; ULTRASTRUCTURE;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; DIPEPTIDES; HUMANS; MELANINS; MICE; MICROSCOPY, ATOMIC FORCE; NEUROBLASTOMA; PEPTIDE FRAGMENTS; SILVER STAINING; SPECTRUM ANALYSIS; SURFACE PLASMON RESONANCE; TIME FACTORS; TRITIUM;

EID: 84923617231     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.12.038     Document Type: Article

References (76)

1. E. Abramov, I. Dolev, H. Fogel, G.D. Ciccotosto, E. Ruff, and I. Slutsky Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses Nat. Neurosci. 12 12 2009 1567 1576
2. E. Alberdi, M.V. Sanchez-Gomez, F. Cavaliere, A. Perez-Samartin, J.L. Zugaza, R. Trullas, M. Domercq, and C. Matute Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors Cell Calcium 47 3 2010 264 272
3. A. Alzheimer Über eine eigenartige Erkrankung der Hirnrinde Cent. Nervenheilkd. Psychiatr. 30 1907 177 179
4. F. Bao, L. Wicklund, P.N. Lacor, W.L. Klein, A. Nordberg, and A. Marutle Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity Neurobiol. Aging 2011
5. S. Barghorn, V. Nimmrich, A. Striebinger, C. Krantz, P. Keller, B. Janson, M. Bahr, M. Schmidt, R.S. Bitner, J. Harlan, E. Barlow, U. Ebert, and H. Hillen Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease J. Neurochem. 95 3 2005 834 847
6. K.F. Bell, and A. Claudio Cuello Altered synaptic function in Alzheimer's disease Eur. J. Pharmacol. 545 1 2006 11 21
7. X. Bi, C.M. Gall, J. Zhou, and G. Lynch Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists Neuroscience 112 4 2002 827 840
8. J. Bieschke, M. Herbst, T. Wiglenda, R.P. Friedrich, A. Boeddrich, F. Schiele, D. Kleckers, J.M. Lopez del Amo, B.A. Gruning, Q. Wang, M.R. Schmidt, R. Lurz, R. Anwyl, S. Schnoegl, M. Fandrich, R.F. Frank, B. Reif, S. Gunther, D.M. Walsh, and E.E. Wanker Small-molecule conversion of toxic oligomers to nontoxic beta-sheet-rich amyloid fibrils Nat. Chem. Biol. 2011
9. J.C. Blanks, S.Y. Schmidt, Y. Torigoe, K.V. Porrello, D.R. Hinton, and R.H. Blanks Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL Neurobiol. Aging 17 3 1996 385 395
10. J.C. Blanks, Y. Torigoe, D.R. Hinton, and R.H. Blanks Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina Neurobiol. Aging 17 3 1996 377 384
11. H. Blum, H. Beier, and H.J. Gross Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels Electrophoresis 8 1987 93 99
12. H. Braak, E. Braak, and J. Bohl Staging of Alzheimer-related cortical destruction Eur. Neurol. 33 6 1993 403 408
13. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
14. M. Citron Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discov. 9 5 2010 387 398
15. F.G. De Felice, D. Wu, M.P. Lambert, S.J. Fernandez, P.T. Velasco, P.N. Lacor, E.H. Bigio, J. Jerecic, P.J. Acton, P.J. Shughrue, E. Chen-Dodson, G.G. Kinney, and W.L. Klein Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers Neurobiol. Aging 2007
16. A. Demuro, I. Parker, and G.E. Stutzmann Calcium signaling and amyloid toxicity in Alzheimer disease J. Biol. Chem. 285 17 2010 12463 12468
17. T. Dentchev, A.H. Milam, V.M. Lee, J.Q. Trojanowski, and J.L. Dunaief Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas Mol. Vis. 9 2003 184 190
18. R.M. Dutescu, Q.X. Li, J. Crowston, C.L. Masters, P.N. Baird, and J.G. Culvenor Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease Graefes Arch. Clin. Exp. Ophthalmol. 247 9 2009 1213 1221
19. A. Ferreira, R.C. Sinjoanu, A. Nicholson, and S. Kleinschmidt Abeta toxicity in primary cultured neurons Methods Mol. Biol. 670 2011 141 153
20. S.T. Ferreira, and W.L. Klein The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease Neurobiol. Learn. Mem. 2011
21. S.T. Ferreira, M.N. Vieira, and F.G. De Felice Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases IUBMB Life 59 4-5 2007 332 345
22. D.S. Friedman, B.J. O'Colmain, B. Munoz, S.C. Tomany, C. McCarty, P.T. de Jong, B. Nemesure, P. Mitchell, J. Kempen Eye Diseases Prevalence Research, G Prevalence of age-related macular degeneration in the United States Arch. Ophthalmol. 122 4 2004 564 572
23. D.S. Friedman, R.C. Wolfs, B.J. O'Colmain, B.E. Klein, H.R. Taylor, S. West, M.C. Leske, P. Mitchell, N. Congdon, and J. Kempen Prevalence of open-angle glaucoma among adults in the United States Arch. Ophthalmol. 122 4 2004 532 538
24. A. Frydman-Marom, M. Rechter, I. Shefler, Y. Bram, D.E. Shalev, and E. Gazit Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies Angew. Chem. Int. Ed. Engl. 48 11 2009 1981 1986
25. A. Frydman-Marom, R. Shaltiel-Karyo, S. Moshe, and E. Gazit The generic amyloid formation inhibition effect of a designed small aromatic beta-breaking peptide Amyloid 18 3 2011 119 127
26. S. Funke, T. van Groen, I. Kadish, D. Bartnik, L. Nagel-Steger, O. Brener, T. Sehl, R. Batra-Safferling, C. Moriscot, G. Schoehn, A.H.C. Horn, A. Müller-Schiffmann, C. Korth, H. Sticht, and D. Willbold Oral treatment with the d-Enantiomeric peptide D3 improves the pathology and behavior of Alzheimers disease transgenic mice ACS Chem. Neurosci. 1 9 2010 639 648
27. K.M. Gehrs, J.R. Jackson, E.N. Brown, R. Allikmets, and G.S. Hageman Complement, age-related macular degeneration and a vision of the future Arch. Ophthalmol. 128 3 2010 349 358
28. M.L. Giuffrida, F. Caraci, B. Pignataro, S. Cataldo, P. De Bona, V. Bruno, G. Molinaro, G. Pappalardo, A. Messina, A. Palmigiano, D. Garozzo, F. Nicoletti, E. Rizzarelli, and A. Copani ß-amyloid monomers are neuroprotective J. Neurosci. 29 34 2009 10582 10587
29. D. Goldblum, A. Kipfer-Kauer, G.M. Sarra, S. Wolf, and B.E. Frueh Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas Investig. Ophthalmol. Vis. Sci. 48 11 2007 5085 5090
30. L. Guo, T.E. Salt, V. Luong, N. Wood, W. Cheung, A. Maass, G. Ferrari, F. Russo-Marie, A.M. Sillito, M.E. Cheetham, S.E. Moss, F.W. Fitzke, and M.F. Cordeiro Targeting amyloid-beta in glaucoma treatment Proc. Natl. Acad. Sci. U. S. A. 104 33 2007 13444 13449
31. J.A. Hardy, and G.A. Higgins Alzheimer's disease: the amyloid cascade hypothesis Science 256 5054 1992 184 185
32. K. Heininger A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes Hum. Psychopharmacol. 14 8 1999 525 581
33. J. Hoh Kam, E. Lenassi, and G. Jeffery Viewing ageing eyes: diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages PloS One 5 10 2010
34. P.K. Iseri, O. Altinas, T. Tokay, and N. Yuksel Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease J. Neuroophthalmol. 26 1 2006 18 24
35. L.V. Johnson, W.P. Leitner, A.J. Rivest, M.K. Staples, M.J. Radeke, and D.H. Anderson The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration Proc. Natl. Acad. Sci. U. S. A. 99 18 2002 11830 11835
36. A. Kipfer-Kauer, S.J. McKinnon, B.E. Frueh, and D. Goldblum Distribution of amyloid precursor protein and amyloid-beta in ocular hypertensive C57BL/6 mouse eyes Curr. Eye Res. 35 9 2010 828 834
37. R. Klein, B.E. Klein, S.C. Tomany, S.M. Meuer, and G.H. Huang Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study Ophthalmology 109 10 2002 1767 1779
38. I. Klyubin, D.M. Walsh, W.K. Cullen, J.V. Fadeeva, R. Anwyl, D.J. Selkoe, and M.J. Rowan Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo Eur. J. Neurosci. 19 10 2004 2839 2846
39. M.J. Koeberle, P.M. Hughes, C.G. Wilson, and G.G. Skellern Development of a liquid chromatography-mass spectrometric method for measuring the binding of memantine to different melanins J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 787 2 2003 313 322
40. N. Kokkoni, K. Stott, H. Amijee, J.M. Mason, and A.J. Doig N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure Biochemistry 45 32 2006 9906 9918
41. J. Kumar, and V. Sim D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease Prion 8 1 2014 119 124
42. P.N. Lacor, M.C. Buniel, P.W. Furlow, A.S. Clemente, P.T. Velasco, M. Wood, K.L. Viola, and W.L. Klein Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease J. Neurosci. 27 4 2007 796 807
43. S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher, and K.H. Ashe A specific amyloid-beta protein assembly in the brain impairs memory Nature 440 7082 2006 352 357
44. M.P. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg, and R.E. Rydel Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity J. Neurosci. 12 2 1992 376 389
45. S.J. McKinnon Glaucoma: ocular Alzheimer's disease? Front. Biosci. 8 2003 s1140 1156
46. R.G. Morris The memory deficits in Alzheimer-type dementia: a review Q. J. Exp. Psychol. 38A 1986 575 602
47. U. Neniskyte, J.J. Neher, and G.C. Brown Neuronal death induced by nanomolar amyloid beta is mediated by primary phagocytosis of neurons by microglia J. Biol. Chem. 286 46 2011 39904 39913
48. A. Ning, J. Cui, E. To, K.H. Ashe, and J. Matsubara Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease Investig. Ophthalmol. Vis. Sci. 49 11 2008 5136 5143
49. K. Ohno-Matsui, H.L. Ramkumar, J. Zhang, and C.C. Chan Parallel findings in age-related macular degeneration and Alzheimer's disease Prog. Retin. Eye Res. 30 4 2011 217 238
50. V. Parisi, R. Restuccia, F. Fattapposta, C. Mina, M.G. Bucci, and F. Pierelli Morphological and functional retinal impairment in Alzheimer's disease patients Clin. Neurophysiol. 112 10 2001 1860 1867
51. L. Pitkanen, V.P. Ranta, H. Moilanen, and A. Urtti Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium Pharm. Res. 24 11 2007 2063 2070
52. D. Puzzo, L. Privitera, E. Leznik, M. Fa, A. Staniszewski, A. Palmeri, and O. Arancio Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus J. Neurosci. 28 53 2008 14537 14545
53. L. Rajendran, M. Honsho, T.R. Zahn, P. Keller, K.D. Geiger, P. Verkade, and K. Simons Alzheimer's disease beta-amyloid peptides are released in association with exosomes Proc. Natl. Acad. Sci. U. S. A. 103 30 2006 11172 11177
54. G. Rammes, A. Hasenjäger, K. Sroka, and C.G. Parsons Aggregation inhibitors reverse ß-amyloid (Aß)-induced inhibition of long term potentiation (LTP) in murine hippocampal slices Soc Neurosci Abstr. 41th Society for Neuroscience Annual Meeting. Washington, USA, 12th-18th November 2011 2011 #47.15
55. J. Rogers, N.R. Cooper, S. Webster, J. Schultz, P.L. McGeer, S.D. Styren, W.H. Civin, L. Brachova, B. Bradt, and P. Ward Complement activation by beta-amyloid in Alzheimer disease Proc. Natl. Acad. Sci. U. S. A. 89 21 1992 10016 10020
56. H. Rottenberg The measurement of membrane potential and deltapH in cells, organelles, and vesicles Methods Enzymol. 55 1979 547 569
57. B. Scorneaux, and T.R. Shryock Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes J. Vet. Pharmacol. Ther. 21 4 1998 257 268
58. D.J. Selkoe Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav. Brain Res. 192 1 2008 106 113
59. G.M. Shankar, B.L. Bloodgood, M. Townsend, D.M. Walsh, D.J. Selkoe, and B.L. Sabatini Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway J. Neurosci. 27 11 2007 2866 2875
60. P.B. Shelat, M. Chalimoniuk, J.H. Wang, J.B. Strosznajder, J.C. Lee, A.Y. Sun, A. Simonyi, and G.Y. Sun Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A(2) in cortical neurons J. Neurochem. 2008
61. J.M. Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease Investig. Ophthalmol. Vis. Sci. 54 1 2013 871 880
62. S. Sokolow, K.M. Henkins, T. Bilousova, C.A. Miller, H.V. Vinters, W. Poon, G.M. Cole, and K.H. Gylys AD synapses contain abundant Abeta monomer and multiple soluble oligomers, including a 56-kDa assembly Neurobiol. Aging 33 8 2011 1545 1555
63. L. Sun, L. Wang, Y. Sun, S.W. Tang, and Y. Hu Protective effects of EUK4010 on beta-amyloid(1-42) induced degeneration of neuronal cells Eur. J. Neurosci. 24 4 2006 1011 1019
64. A. Surguchev, and A. Surguchov Conformational diseases: looking into the eyes Brain Res. Bull. 81 1 2010 12 24
65. T. Tomiyama, S. Matsuyama, H. Iso, T. Umeda, H. Takuma, K. Ohnishi, K. Ishibashi, R. Teraoka, N. Sakama, T. Yamashita, K. Nishitsuji, K. Ito, H. Shimada, M.P. Lambert, W.L. Klein, and H. Mori A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo J. Neurosci. 30 14 2010 4845 4856
66. K. Tsuruma, Y. Tanaka, M. Shimazawa, and H. Hara Induction of amyloid precursor protein by the neurotoxic peptide, amyloid-beta 25-35, causes retinal ganglion cell death J. Neurochem. 113 6 2010 1545 1554
67. Z. van Helmond, J.S. Miners, P.G. Kehoe, and S. Love Higher soluble amyloid beta concentration in frontal cortex of young adults than in normal elderly or Alzheimer's disease Brain Pathol. 20 4 2010 787 793
68. N. Von Thun und Hohenstein-Blaul, O.W. Gramlich, M. Ruitenberg, A. Gravius, N. Pfeiffer, and F.H. Grus ß-amyloid Deposition in Human Glaucomatous Retinae Revealed by Proteomic and Immunohistochemical Analyses 5.05.2013-9.05.2013 2013 ARVO Seattle, USA 1139
69. D.T. Walsh, L. Bresciani, D. Saunders, M.F. Manca, A. Jen, S.M. Gentleman, and L.S. Jen Amyloid beta peptide causes chronic glial cell activation and neuro-degeneration after intravitreal injection Neuropathol. Appl. Neurobiol. 31 5 2005 491 502
70. J. Wang, K. Ohno-Matsui, T. Yoshida, N. Shimada, S. Ichinose, T. Sato, M. Mochizuki, and I. Morita Amyloid-beta up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: another mechanism of complement activation in age-related macular degeneration J. Cell. Physiol. 220 1 2009 119 128
71. K.C. Wilcox, P.N. Lacor, J. Pitt, and W.L. Klein Abeta oligomer-induced synapse degeneration in Alzheimer's disease Cell. Mol. Neurobiol. 31 6 2011 939 948
72. W. Xia Brain amyloid beta protein and memory disruption in Alzheimer's disease Neuropsychiatr. Dis. Treat. 6 2010 605 611
73. B.A. Yankner Mechanisms of neuronal degeneration in Alzheimer's disease Neuron 16 5 1996 921 932
74. S. Yoneda, H. Hara, A. Hirata, M. Fukushima, Y. Inomata, and H. Tanihara Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases Jpn. J. Ophthalmol. 49 2 2005 106 108
75. T. Yoshida, K. Ohno-Matsui, S. Ichinose, T. Sato, N. Iwata, T.C. Saido, T. Hisatomi, M. Mochizuki, and I. Morita The potential role of amyloid beta in the pathogenesis of age-related macular degeneration J. Clin. Investig. 115 10 2005 2793 2800
76. X. Zhu, W. Zhou, Y. Cui, L. Zhu, J. Li, Z. Xia, B. Shao, H. Wang, and H. Chen Muscarinic activation attenuates abnormal processing of beta-amyloid precursor protein induced by cobalt chloride-mimetic hypoxia in retinal ganglion cells Biochem. Biophys. Res. Commun. 384 1 2009 110 113